Ainhoa Madariaga, Medical Oncologist at University Hospital October 12, shared a post on X:
”Delighted to share the results of Study420 at ESMOGynae2026 evaluating Carbo-Mirv in FRα+ platinum-sensitive Ovarian Cancer.
- N=120. ~50% prior PARPi exposed
- Prior PARPi alone did not impact outcomes
- Pts progressing during PARPi had ORR and PFS.”
Other articles about Ovarian Cancer on OncoDaily.
